Zhuo-Wei Hu (Zhuowei Hu)

Years Active: 2020-2022
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Xingfeng Liu, Kai Wang, Shaocong Hou, Qian Jiang, Chunxiao Ma, Qijin Zhao, Lijuan Kong, Jingwen Chen, Zhenhe Wang, Huabing Zhang, Tao Yuan, Yuxiu Li, Yi Huan, Zhufang Shen, Zhuo-Wei Hu, Zhifeng Huang, Bing Cui, Ping-Ping Li
Insulin induces insulin receptor degradation in the liver through EphB4. Nature metabolism 4 (9) (2022)
Shan-Shan Liu, Jie Qi, Zu-Dong Teng, Fu-Tao Tian, Xiao-Xi Lv, Ke Li, Ya-Jie Song, Wei-Dong Xie, Zhuo-Wei Hu, Xia Li
Resistomycin attenuates triple-negative breast cancer progression by inhibiting E3 ligase Pellino-1 and inducing SNAIL/SLUG degradation. Signal transduction and targeted therapy 5 (1) (2020)
Ke Li, Feng Wang, Zhao-Na Yang, Ting-Ting Zhang, Yu-Fen Yuan, Chen-Xi Zhao, Zaiwuli Yeerjiang, Bing Cui, Fang Hua, Xiao-Xi Lv, Xiao-Wei Zhang, Jiao-Jiao Yu, Shan-Shan Liu, Jin-Mei Yu, Shuang Shang, Yang Xiao, Zhuo-Wei Hu
TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation. Nature communications 11 (1) (2020)

Zhuo-Wei Hu.css-eqlu8i{font-size:small;padding-left:4px;} (Zhuowei Hu)